Maria Jesus Perugorria

List of Publications by Year
in descending order

43	4,352	257357 24	254106 43
papers	citations	h-index	g-index

43	43	43	5550
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. Hepatology, 2022, 76, 1617-1633.	3.6	15
2	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	1.8	11
3	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 585-604.	8.2	15
4	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. Journal of Hepatology, 2022, 77, 991-1004.	1.8	22
5	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. Hepatology, 2021, 73, 186-203.	3.6	7
6	Pathogenesis of Cholangiocarcinoma. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 433-463.	9.6	63
7	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. Journal of Hepatology, 2021, 74, 394-406.	1.8	14
8	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut, 2021, 70, 1345-1361.	6.1	59
9	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. Cancer Research, 2021, 81, 2874-2887.	0.4	27
10	Inhibition of NAEâ€dependent protein hyperâ€NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. United European Gastroenterology Journal, 2021, 9, 848-859.	1.6	7
11	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. Journal of Hepatology, 2021, 75, 363-376.	1.8	29
12	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. Liver International, 2020, 40, 1670-1685.	1.9	22
13	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	1.8	63
14	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	8.2	1,155
15	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 497-511.	8.2	73
16	The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver International, 2019, 39, 63-78.	1.9	109
17	Wntâ€“Î²-catenin signalling in liver development, health and disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 121-136.	8.2	341
18	Cholangiocyteâ€toâ€Hepatocyte Differentiation: A Contextâ€Dependent Process and an Opportunity for Regenerative Medicine. Hepatology, 2019, 69, 480-483.	3.6	6

#	Article	IF	Citations
19	Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. Gut, 2019, 68, 533-546.	6.1	96
20	MicroRNA (miR)â€433 and miRâ€22 dysregulations induce histoneâ€deacetylaseâ€6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology, 2018, 68, 561-573.	3.6	54
21	Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients. Hepatology, 2018, 68, 811-814.	3.6	4
22	MicroRNAâ€506 promotes primary biliary cholangitisâ€“like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440.	3.6	72
23	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477.	1.8	72
24	Extracellular Vesicles in Hepatobiliary Malignancies. Frontiers in Immunology, 2018, 9, 2270.	2.2	29
25	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. Journal of Hepatology, 2018, 69, 1371-1383.	1.8	35
26	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83.	1.8	81
27	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Digestive Diseases, 2017, 35, 275-281.	0.8	8
28	O-GlcNAcylation: Undesired tripmate but an opportunity for treatment in NAFLD-HCC. Journal of Hepatology, 2017, 67, 218-220.	1.8	3
29	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	3.6	218
30	Novel causative genes for polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 391-392.	8.2	15
31	Effect of pravastatin on the survival of patients with advanced gastric cancer. Oncotarget, 2016, 7, 4379-4384.	0.8	15
32	PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surgery for Obesity and Related Diseases, 2016, 12, 1838-1846.	1.0	60
33	Elevated interleukinâ€8 in bile of patients with primary sclerosing cholangitis. Liver International, 2016, 36, 1370-1377.	1.9	34
34	TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury. Journal of Immunology, 2016, 196, 4298-4310.	0.4	16
35	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	8.2	964
36	More insight into the diversity of cholangiocyte ciliopathies. Journal of Hepatology, 2016, 65, 1083-1085.	1.8	1

#	Article	IF	Citations
37	MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 15-27.	0.7	20
38	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961.	1.8	56
39	Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761.	8.2	80
40	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	6.1	55
41	Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice. Hepatology, 2013, 57, 1238-1249.	3.6	41
42	Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology, 2012, 56, 1129-1139.	3.6	108
43	Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nature Medicine, 2011, 17, 1668-1673.	15.2	177